Severe Asthma Research Program (SARP)- San Francisco Clinical Site

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

151 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-11-30

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The mission of SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Severe Asthma Research Program

NCT01606826

Asthma

ACTIVE_NOT_RECRUITING

Severe Asthma Research Program - Wake Forest University

NCT01750411

Asthma Severe Persistent Asthma

COMPLETED

Washington University Severe Asthma Research Program III

NCT01716494

Asthma

UNKNOWN

University of Wisconsin Severe Asthma Research Program III

NCT01760915

Asthma

COMPLETED

The Severe Asthma Research Program III-Boston Clinical Site

NCT01761630

Asthma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The mission of the SARP is to improve the understanding of severe asthma to develop better treatments. The SARP will gain a better understanding of asthma and its endotypes, in children and adults, by defining the disease at the molecular and cellular levels in the context of the temporal phenotypic expression of the disease. To this end, the SARP investigators will utilize both mechanistic and evoked phenotype approaches to: 1) characterize developmental molecular, cellular and physiologic phenotypes in children and adults with mild to severe asthma, and 2) to further elucidate the evolving pathobiology and pathogenesis of severe asthma and its sub-phenotypes and 3) compare these features over time.

This approach involves a shared longitudinal protocol conducted across all participating centers which includes common information on all SARP participants. Additionally, the SARP-SF has identified mechanistic research questions to be included in the shared longitudinal protocol. This will be explored through additional sample collections of sputum and fluids and biopsied tissue collected by bronchoscopy. Together, these longitudinal and mechanistic approaches will enable prediction of phenotype stability/fluctuation and pharmacologic responses and identification of novel, disease-modifying targets for treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mild-to-Moderate Asthma

Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.

No interventions assigned to this group

Severe Asthma

Major Criteria: (1 required)

1. Treatment with oral corticosteroids for at least 6 of the previous 12 months
2. Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months

Minor Criteria: (2 required)

1. Daily treatment with an asthma controller medication in addition to ICS, or
2. Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or
3. Persistent airway obstruction with baseline FEV1 \<80% predicted, or
4. ≥ 1 urgent visits for asthma in the previous 12 months, or
5. ≥ 3 systemic corticosteroid bursts in the previous 12 months, or
6. Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or
7. A near-fatal asthma event (i.e., intubation) in the past

No interventions assigned to this group

Healthy Controls

Those without asthma or other chronic lung disease.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* FEV1 bronchodilator reversibility ≥12% or airway hyperresponsiveness reflected by a methacholine PC20 ≤16 mg/mL
* An exception will be made for enrollees whose FEV1 is \< 50% predicted (\<70% in children aged 6 to 17 years), precluding methacholine challenge testing. If bronchodilator reversibility is \<12% in these participants, a diagnosis of asthma acceptable to the investigator is sufficient for inclusion in SARP.

Exclusion Criteria

* Pregnancy during the characterization phase,
* Current smoking,
* Smoking history \> 10 pack years if ≥30 years of age, or smoking history \> 5 pack years if \<30 years of age,
* Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways,
* History of premature birth before 35 weeks gestation,
* Unwillingness to receive an intramuscular triamcinolone acetonide injection
* Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures,
* Planning to relocate from the clinical center area before study completion,
* Any other criteria that place the subject at unnecessary risk according to the judgment of the Principal Investigator and/or attending physician(s) of record, or
* Currently participating in an investigational drug trial.

Healthy Controls:

* History of chronic diseases that affect the lungs.
* A history suggestive of allergic rhinitis, eczema or chronic sinusitis.
* An improvement in FEV1 of more than 12% following 4 puffs of albuterol.
* Smoking history \> 10 pack years if ≥30 years of age, or smoking history \> 5 pack years if \<30 years of age, or any smoking within the past year.
* Respiratory tract infection within the past 4 weeks.
* Pregnancy.
* History of premature birth (\<35 weeks).

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes